A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, September 29, 2014
Primary, Secondary Progressive MS Therapy to be Tested in Phase 2 Trial by MediciNova
MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in progressive multiple sclerosis patients. As of September 15th, 150 of an expected 250 patients have enrolled for treatment, and the trial is on track to complete enrollment by the second quarter of 2015.
“We are very pleased to have completed 60% of the enrollment in this study,” said Yuichi Iwaki, MD, PhD, Presiden and CEO of MediciNova, in a news release. “We look forward to providing further updates as the study progresses.”
The study is headed by Robert Fox, MD, MS, FAAN, Vice-Chair for Research if the Neurological Institute of the Cleveland Clinic. NeuroNEXT clinical trial network is conducting the study at 28 academic medical centers, and funding is provided by the National Institutes of Health.